Alfonso Rodriguez Espada/LinkedIn
Sep 20, 2025, 16:20
Alfonso Rodriguez Espada Validates FXII as a Safe Antithrombotic Target
Alfonso Rodriguez Espada, Postdoctoral Fellow at BIDMC and Broad Institute of Harvard and MIT, shared a post on LinkedIn:
“We showed that heterozygous rare FXII variant carriers are protected against venous thromboembolism (VTE) using high confidence loss-of-function variants from the UK Biobank and NIH All of Us Program while also showing that these mutations are not associated with bleeding or sepsis as speculated in previous reports. Data was validated in vivo using MGB blood samples and mice to further evaluate thrombin generation/activity. This data further pushes FXII as a potential drug target that could prevent VTE in a safe and effective way!”
Read more here.
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning